Download PDF

Journal of Microbiology

, Volume 54, Issue 3, pp 192–201 | Cite as

The development of fluconazole resistance in Candida albicans – an example of microevolution of a fungal pathogen

Review Biology of Human Fungal Pathogen
First Online:
Received:
Revised:
Accepted:

Abstract

The yeast Candida albicans is a member of the microbiota in the gastrointestinal and urogenital tracts of most healthy persons, but it can also cause symptomatic infections, especially in immunocompromised patients. During the life-long association with its human host, C. albicans generates genetically altered variants that are better adapted to changes in their environment. A prime example of this microevolution is the development of resistance to the commonly used drug fluconazole, which inhibits ergosterol biosynthesis, during antimycotic therapy. Fluconazole resistance can be caused by mutations in the drug target, by changes in the sterol biosynthesis pathway, and by gain-of-function mutations in transcription factors that result in the constitutive upregulation of ergosterol biosynthesis genes and multidrug efflux pumps. Fluconazole also induces genomic rearrangements that result in gene amplification and loss of heterozygosity for resistance mutations, which further increases drug resistance. These genome alterations may affect extended chromosomal regions and have additional phenotypic consequences. A striking case is the loss of heterozygosity for the mating type locus MTL in many fluconazole-resistant clinical isolates, which allows the cells to switch to the mating-competent opaque phenotype. This, in turn, raises the possibility that sexual recombination between different variants of an originally clonal, drug-susceptible population may contribute to the generation of highly fluconazole-resistant strains with multiple resistance mechanisms. The gain-of-function mutations in transcription factors, which result in deregulated gene expression, also cause reduced fitness. In spite of this, many clinical isolates that contain such mutations do not exhibit fitness defects, indicating that they have overcome the costs of drug resistance with further evolution by still unknown mechanisms.

Keywords

drug resistance fitness costs gain-of-function mutation genome alterations loss of heterozygosity 
Download to read the full article text

References

  1. Alarco, A.M. and Raymond, M. 1999. The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans. J. Bacteriol. 181, 700–708.PubMedCentralPubMedGoogle Scholar
  2. Alby, K. and Bennett, R.J. 2009. Stress-induced phenotypic switching in Candida albicans. Mol. Biol. Cell. 20, 3178–3191.PubMedCentralCrossRefPubMedGoogle Scholar
  3. Andes, D., Forrest, A., Lepak, A., Nett, J., Marchillo, K., and Lincoln, L. 2006. Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob. Agents Chemother. 50, 2374–2383.PubMedCentralCrossRefPubMedGoogle Scholar
  4. Angiolella, L., Stringaro, A.R., De Bernardis, F., Posteraro, B., Bonito, M., Toccacieli, L., Torosantucci, A., Colone, M., Sanguinetti, M., Cassone, A., et al. 2008. Increase of virulence and its phenotypic traits in drug-resistant strains of Candida albicans. Antimicrob. Agents Chemother. 52, 927–936.PubMedCentralCrossRefPubMedGoogle Scholar
  5. Asai, K., Tsuchimori, N., Okonogi, K., Perfect, J.R., Gotoh, O., and Yoshida, Y. 1999. Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob. Agents Chemother. 43, 1163–1169.PubMedCentralPubMedGoogle Scholar
  6. Berman, J. and Hadany, L. 2012. Does stress induce (para)sex? Implications for Candida albicans evolution. Trends Genet. 28, 197–203.PubMedCentralCrossRefPubMedGoogle Scholar
  7. Calvet, H.M., Yeaman, M.R., and Filler, S.G. 1997. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob. Agents Chemother. 41, 535–539.PubMedCentralPubMedGoogle Scholar
  8. Chau, A.S., Gurnani, M., Hawkinson, R., Laverdiere, M., Cacciapuoti, A., and McNicholas, P.M. 2005. Inactivation of sterol Δ5,6-desaturase attenuates virulence in Candida albicans. Antimicrob. Agents Chemother. 49, 3646–3651.PubMedCentralCrossRefPubMedGoogle Scholar
  9. Coste, A., Selmecki, A., Forche, A., Diogo, D., Bougnoux, M.E., d’Enfert, C., Berman, J., and Sanglard, D. 2007. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot. Cell 6, 1889–1904.PubMedCentralCrossRefPubMedGoogle Scholar
  10. Coste, A., Turner, V., Ischer, F., Morschhäuser, J., Forche, A., Selmecki, A., Berman, J., Bille, J., and Sanglard, D. 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172, 2139–2156.PubMedCentralCrossRefPubMedGoogle Scholar
  11. Coste, A.T., Crittin, J., Bauser, C., Rohde, B., and Sanglard, D. 2009. Functional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. Eukaryot. Cell 8, 1250–1267.PubMedCentralCrossRefPubMedGoogle Scholar
  12. Coste, A.T., Karababa, M., Ischer, F., Bille, J., and Sanglard, D. 2004. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot. Cell 3, 1639–1652.PubMedCentralCrossRefPubMedGoogle Scholar
  13. Cruz, M.C., Goldstein, A.L., Blankenship, J.R., Del Poeta, M., Davis, D., Cardenas, M.E., Perfect, J.R., McCusker, J.H., and Heitman, J. 2002. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J. 21, 546–559.PubMedCentralCrossRefPubMedGoogle Scholar
  14. Dunkel, N., Blaβ, J., Rogers, P.D., and Morschhäuser, J. 2008a. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol. Microbiol. 69, 827–840.PubMedCentralCrossRefPubMedGoogle Scholar
  15. Dunkel, N., Liu, T.T., Barker, K.S., Homayouni, R., Morschhäuser, J., and Rogers, P.D. 2008b. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot. Cell 7, 1180–1190.PubMedCentralCrossRefPubMedGoogle Scholar
  16. Favre, B., Didmon, M., and Ryder, N.S. 1999. Multiple amino acid substitutions in lanosterol 14a-demethylase contribute to azole resistance in Candida albicans. Microbiology 145, 2715–2725.CrossRefPubMedGoogle Scholar
  17. Flowers, S.A., Barker, K.S., Berkow, E.L., Toner, G., Chadwick, S.G., Gygax, S.E., Morschhäuser, J., and Rogers, P.D. 2012. Gain-offunction mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot. Cell 11, 1289–1299.PubMedCentralCrossRefPubMedGoogle Scholar
  18. Flowers, S.A., Colon, B., Whaley, S.G., Schuler, M.A., and Rogers, P.D. 2015. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob. Agents Chemother. 59, 450–460.PubMedCentralCrossRefPubMedGoogle Scholar
  19. Forche, A., Abbey, D., Pisithkul, T., Weinzierl, M.A., Ringstrom, T., Bruck, D., Petersen, K., and Berman, J. 2011. Stress alters rates and types of loss of heterozygosity in Candida albicans. mBio 2, e00129–11.PubMedCentralCrossRefPubMedGoogle Scholar
  20. Forche, A., Alby, K., Schaefer, D., Johnson, A.D., Berman, J., and Bennett, R.J. 2008. The parasexual cycle in Candida albicans provides an alternative pathway to meiosis for the formation of recombinant strains. PLoS Biol. 6, e110.PubMedCentralCrossRefPubMedGoogle Scholar
  21. Ford, C.B., Funt, J.M., Abbey, D., Issi, L., Guiducci, C., Martinez, D.A., Delorey, T., Li, B.Y., White, T.C., Cuomo, C., et al. 2015. The evolution of drug resistance in clinical isolates of Candida albicans. Elife 4, e00662.CrossRefPubMedGoogle Scholar
  22. Franz, R., Kelly, S.L., Lamb, D.C., Kelly, D.E., Ruhnke, M., and Morschhäuser, J. 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42, 3065–3072.PubMedCentralPubMedGoogle Scholar
  23. Franz, R., Ruhnke, M., and Morschhäuser, J. 1999. Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses 42, 453–458.CrossRefPubMedGoogle Scholar
  24. Harrison, B.D., Hashemi, J., Bibi, M., Pulver, R., Bavli, D., Nahmias, Y., Wellington, M., Sapiro, G., and Berman, J. 2014. A tetraploid intermediate precedes aneuploid formation in yeasts exposed to fluconazole. PLoS Biol. 12, e1001815.PubMedCentralCrossRefPubMedGoogle Scholar
  25. Hayama, K., Ishibashi, H., Ishijima, S.A., Niimi, K., Tansho, S., Ono, Y., Monk, B.C., Holmes, A.R., Harding, D.R., Cannon, R.D., et al. 2012. A D-octapeptide drug efflux pump inhibitor acts synergistically with azoles in a murine oral candidiasis infection model. FEMS Microbiol. Lett. 328, 130–137.CrossRefPubMedGoogle Scholar
  26. Heilmann, C.J., Schneider, S., Barker, K.S., Rogers, P.D., and Morschhäuser, J. 2010. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. Antimicrob. Agents Chemother. 54, 353–359.PubMedCentralCrossRefPubMedGoogle Scholar
  27. Hoot, S.J., Smith, A.R., Brown, R.P., and White, T.C. 2011. An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 55, 940–942.PubMedCentralCrossRefPubMedGoogle Scholar
  28. Huang, G., Srikantha, T., Sahni, N., Yi, S., and Soll, D.R. 2009. CO2 regulates white-to-opaque switching in Candida albicans. Curr. Biol. 19, 330–334.PubMedCentralCrossRefPubMedGoogle Scholar
  29. Huang, G., Yi, S., Sahni, N., Daniels, K.J., Srikantha, T., and Soll, D.R. 2010. N-acetylglucosamine induces white to opaque switching, a mating prerequisite in Candida albicans. PLoS Pathog. 6, e1000806.PubMedCentralCrossRefPubMedGoogle Scholar
  30. Huang, M., McClellan, M., Berman, J., and Kao, K.C. 2011. Evolutionary dynamics of Candida albicans during in vitro evolution. Eukaryot. Cell 10, 1413–1421.PubMedCentralCrossRefPubMedGoogle Scholar
  31. Jain, P., Akula, I., and Edlind, T. 2003. Cyclic AMP signaling pathway modulates susceptibility of Candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 47, 3195–3201.PubMedCentralCrossRefPubMedGoogle Scholar
  32. Kakeya, H., Miyazaki, Y., Miyazaki, H., Nyswaner, K., Grimberg, B., and Bennett, J.E. 2000. Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob. Agents Chemother. 44, 2985–2990.PubMedCentralCrossRefPubMedGoogle Scholar
  33. Kelly, S.L., Lamb, D.C., and Kelly, D.E. 1999a. Y132H substitution in Candida albicans sterol 14a-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol. Lett. 180, 171–175.PubMedGoogle Scholar
  34. Kelly, S.L., Lamb, D.C., Kelly, D.E., Manning, N.J., Loeffler, J., Hebart, H., Schumacher, U., and Einsele, H. 1997. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6-desaturation. FEBS Lett. 400, 80–82.CrossRefPubMedGoogle Scholar
  35. Kelly, S.L., Lamb, D.C., Loeffler, J., Einsele, H., and Kelly, D.E. 1999b. The G464S amino acid substitution in Candida albicans sterol 14a-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem. Biophys. Res. Commun. 262, 174–179.CrossRefPubMedGoogle Scholar
  36. Kusch, H., Biswas, K., Schwanfelder, S., Engelmann, S., Rogers, P.D., Hecker, M., and Morschhäuser, J. 2004. A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains. Mol. Genet. Genomics 271, 554–565.CrossRefPubMedGoogle Scholar
  37. Lamb, D.C., Kelly, D.E., White, T.C., and Kelly, S.L. 2000. The R467K amino acid substitution in Candida albicans sterol 14a- demethylase causes drug resistance through reduced affinity. Antimicrob. Agents Chemother. 44, 63–67.PubMedCentralCrossRefPubMedGoogle Scholar
  38. Lohberger, A., Coste, A.T., and Sanglard, D. 2014. Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence. Eukaryot. Cell 13, 127–142.PubMedCentralCrossRefPubMedGoogle Scholar
  39. MacPherson, S., Akache, B., Weber, S., De Deken, X., Raymond, M., and Turcotte, B. 2005. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob. Agents Chemother. 49, 1745–1752.PubMedCentralCrossRefPubMedGoogle Scholar
  40. Mansfield, B.E., Oltean, H.N., Oliver, B.G., Hoot, S.J., Leyde, S.E., Hedstrom, L., and White, T.C. 2010. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog. 6, e1001126.PubMedCentralCrossRefPubMedGoogle Scholar
  41. Marr, K.A., Lyons, C.N., Ha, K., Rustad, T.R., and White, T.C. 2001. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob. Agents Chemother. 45, 52–59.PubMedCentralCrossRefPubMedGoogle Scholar
  42. Marr, K.A., Lyons, C.N., Rustad, T.R., Bowden, R.A., and White, T.C. 1998. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob. Agents Chemother. 42, 2584–2589.PubMedCentralPubMedGoogle Scholar
  43. Martel, C.M., Parker, J.E., Bader, O., Weig, M., Gross, U., Warrilow, A.G., Rolley, N., Kelly, D.E., and Kelly, S.L. 2010. Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrob. Agents Chemother. 54, 4527–4533.PubMedCentralCrossRefPubMedGoogle Scholar
  44. Martinez, M., Lopez-Ribot, J.L., Kirkpatrick, W.R., Bachmann, S.P., Perea, S., Ruesga, M.T., and Patterson, T.F. 2002. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J. Antimicrob. Chemother. 49, 515–524.CrossRefPubMedGoogle Scholar
  45. Miller, M.G. and Johnson, A.D. 2002. White-opaque switching in Candida albicans is controlled by mating-type locus homeodomain proteins and allows efficient mating. Cell 110, 293–302.CrossRefPubMedGoogle Scholar
  46. Miyazaki, T., Miyazaki, Y., Izumikawa, K., Kakeya, H., Miyakoshi, S., Bennett, J.E., and Kohno, S. 2006. Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance. Antimicrob. Agents Chemother. 50, 580–586.PubMedCentralCrossRefPubMedGoogle Scholar
  47. Miyazaki, Y., Geber, A., Miyazaki, H., Falconer, D., Parkinson, T., Hitchcock, C., Grimberg, B., Nyswaner, K., and Bennett, J.E. 1999. Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans. Gene 236, 43–51.CrossRefPubMedGoogle Scholar
  48. Morio, F., Pagniez, F., Lacroix, C., Miegeville, M., and Le Pape, P. 2012. Amino acid substitutions in the Candida albicans sterol Δ5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. J. Antimicrob. Chemother. 67, 2131–2138.CrossRefPubMedGoogle Scholar
  49. Morschhäuser, J., Barker, K.S., Liu, T.T., Blaβ- Warmuth, J., Homayouni, R., and Rogers, P.D. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3, e164.PubMedCentralCrossRefPubMedGoogle Scholar
  50. Morschhäuser, J., Michel, S., and Staib, P. 1999. Sequential gene disruption in Candida albicans by FLP-mediated site-specific recombination. Mol. Microbiol. 32, 547–556.CrossRefPubMedGoogle Scholar
  51. Perea, S., Lopez-Ribot, J.L., Kirkpatrick, W.R., McAtee, R.K., Santillan, R.A., Martinez, M., Calabrese, D., Sanglard, D., and Patterson, T.F. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45, 2676–2684.PubMedCentralCrossRefPubMedGoogle Scholar
  52. Ramírez-Zavala, B., Reuβ, O., Park, Y.N., Ohlsen, K., and Morschhäuser, J. 2008. Environmental induction of white-opaque switching in Candida albicans. PLoS Pathog. 4, e1000089.PubMedCentralCrossRefPubMedGoogle Scholar
  53. Rustad, T.R., Stevens, D.A., Pfaller, M.A., and White, T.C. 2002. Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology 148, 1061–1072.CrossRefPubMedGoogle Scholar
  54. Saidane, S., Weber, S., De Deken, X., St-Germain, G., and Raymond, M. 2006. PDR16-mediated azole resistance in Candida albicans. Mol. Microbiol. 60, 1546–1562.CrossRefPubMedGoogle Scholar
  55. Sanglard, D., Ischer, F., Koymans, L., and Bille, J. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14a-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42, 241–253.PubMedCentralCrossRefPubMedGoogle Scholar
  56. Sanglard, D., Ischer, F., Marchetti, O., Entenza, J., and Bille, J. 2003a. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol. Microbiol. 48, 959–976.CrossRefPubMedGoogle Scholar
  57. Sanglard, D., Ischer, F., Monod, M., and Bille, J. 1996. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40, 2300–2305.PubMedCentralPubMedGoogle Scholar
  58. Sanglard, D., Ischer, F., Monod, M., and Bille, J. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143, 405–416.CrossRefPubMedGoogle Scholar
  59. Sanglard, D., Ischer, F., Parkinson, T., Falconer, D., and Bille, J. 2003b. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob. Agents Chemother. 47, 2404–2412.PubMedCentralCrossRefPubMedGoogle Scholar
  60. Sanglard, D., Kuchler, K., Ischer, F., Pagani, J.L., Monod, M., and Bille, J. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39, 2378–2386.PubMedCentralCrossRefPubMedGoogle Scholar
  61. Sasse, C., Dunkel, N., Schäfer, T., Schneider, S., Dierolf, F., Ohlsen, K., and Morschhäuser, J. 2012. The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in Candida albicans. Mol. Microbiol. 86, 539–556.CrossRefPubMedGoogle Scholar
  62. Schillig, R. and Morschhäuser, J. 2013. Analysis of a fungus-specific transcription factor family, the Candida albicans zinc cluster proteins, by artificial activation. Mol. Microbiol. 89, 1003–1017.CrossRefPubMedGoogle Scholar
  63. Schubert, S., Barker, K.S., Znaidi, S., Schneider, S., Dierolf, F., Dunkel, N., Aid, M., Boucher, G., Rogers, P.D., Raymond, M., et al. 2011. Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob. Agents Chemother. 55, 2212–2223.PubMedCentralCrossRefPubMedGoogle Scholar
  64. Schubert, S., Rogers, P.D., and Morschhäuser, J. 2008. Gain-offunction mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole- resistant Candida dubliniensis strains. Antimicrob. Agents Chemother. 52, 4274–4280.PubMedCentralCrossRefPubMedGoogle Scholar
  65. Schulz, B., Weber, K., Schmidt, A., Borg-von Zepelin, M., and Ruhnke, M. 2011. Difference in virulence between fluconazole- susceptible and fluconazole-resistant Candida albicans in a mouse model. Mycoses 54, e522530.CrossRefGoogle Scholar
  66. Selmecki, A., Forche, A., and Berman, J. 2006. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313, 367–370.PubMedCentralCrossRefPubMedGoogle Scholar
  67. Selmecki, A., Gerami-Nejad, M., Paulson, C., Forche, A., and Berman, J. 2008. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol. Microbiol. 68, 624–641.CrossRefPubMedGoogle Scholar
  68. Selmecki, A.M., Dulmage, K., Cowen, L.E., Anderson, J.B., and Berman, J. 2009. Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet. 5, e1000705.PubMedCentralCrossRefPubMedGoogle Scholar
  69. Silver, P.M., Oliver, B.G., and White, T.C. 2004. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot. Cell 3, 1391–1397.PubMedCentralCrossRefPubMedGoogle Scholar
  70. Talibi, D. and Raymond, M. 1999. Isolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae. J. Bacteriol. 181, 231–240.PubMedCentralPubMedGoogle Scholar
  71. Tsao, S., Rahkhoodaee, F., and Raymond, M. 2009. Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob. Agents Chemother. 53, 1344–1352.PubMedCentralCrossRefPubMedGoogle Scholar
  72. Vale-Silva, L.A., Coste, A.T., Ischer, F., Parker, J.E., Kelly, S.L., Pinto, E., and Sanglard, D. 2012. Azole resistance by loss of function of the sterol Δ5,6-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrob. Agents Chemother. 56, 1960–1968.PubMedCentralCrossRefPubMedGoogle Scholar
  73. Wang, Y., Liu, J.Y., Shi, C., Li, W.J., Zhao, Y., Yan, L., and Xiang, M.J. 2015. Mutations in transcription factor Mrr2p contribute to fluconazole resistance in clinical isolates of Candida albicans. Int. J. Antimicrob. Agents 46, 552–559.CrossRefPubMedGoogle Scholar
  74. White, T.C. 1997a. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41, 1482–1487.PubMedCentralPubMedGoogle Scholar
  75. White, T.C. 1997b. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14a demethylase in Candida albicans. Antimicrob. Agents Chemother. 41, 1488–1494.PubMedCentralPubMedGoogle Scholar
  76. White, T.C., Marr, K.A., and Bowden, R.A. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11, 382–402.PubMedCentralPubMedGoogle Scholar
  77. Wirsching, S., Michel, S., and Morschhäuser, J. 2000. Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol. Microbiol. 36, 856–865.CrossRefPubMedGoogle Scholar
  78. Znaidi, S., De Deken, X., Weber, S., Rigby, T., Nantel, A., and Raymond, M. 2007. The zinc cluster transcription factor Tac1p regulates PDR16 expression in Candida albicans. Mol. Microbiol. 66, 440–452.CrossRefPubMedGoogle Scholar
  79. Znaidi, S., Weber, S., Al-Abdin, O.Z., Bomme, P., Saidane, S., Drouin, S., Lemieux, S., De Deken, X., Robert, F., and Raymond, M. 2008. Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance. Eukaryot. Cell 7, 836–847.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© The Microbiological Society of Korea and Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Institute for Molecular Infection BiologyUniversity of WürzburgWürzburgGermany

Personalised recommendations